{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Scholar Rock Highlights 2025 Strategic Priorities - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"RZ8Ma3GAAJ\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scholar-rock-highlights-2025-strategic-priorities\/\">Scholar Rock Highlights 2025 Strategic Priorities<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/scholar-rock-highlights-2025-strategic-priorities\/embed\/#?secret=RZ8Ma3GAAJ\" width=\"600\" height=\"338\" title=\"&#8220;Scholar Rock Highlights 2025 Strategic Priorities&#8221; &#8212; Market Newsdesk\" data-secret=\"RZ8Ma3GAAJ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Scholar Rock Highlights 2025 Strategic Priorities &#8211; BLA and MAA submission for apitegromab in SMA on track for 1Q 2025; if approved, U.S. launch expected in 4Q 2025 &#8211; Initiating Phase 2 OPAL clinical trial in SMA patients under two years old in mid-2025 &#8211; Data from Phase 2 EMBRAZE trial evaluating apitegromab in obesity expected in 2Q 2025 &#8211; Filing of IND application for SRK-439 on track for 3Q 2025 &#8211; Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 9:45 a.m. PT (12:45 p.m. ET) CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108353769r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"}